Enhancing Titers of Therapeutic Lentiviral Vectors using PKC Agonists
The 3 Rs Of Replication-Competent Lentivirus (RCL) Formation Risk: Real, Rare, or Artificial?
Optimising the Production of the 4th Generation Lentiviral Vector (LV) TetraVecta™ System: Towards Plug-and-Play LV Manufacturing
The Impact of Individual Helper Genes on AAV Productivity
Evaluation of Salt-Tolerant Endonucleases for Lentiviral Vector Purification
Enhancing Upstream Processes for High-Yield, High-Quality AAV Vector Production Using a Novel In-House Cell Line
Diving Deeper: Using a SYBR Gold Capsid Ejection Assay as an Orthogonal Method of Measuring Potency and VP1 Deamidation in AAV9 Drug Product Samples
Accelerate Time to Clinic: A Platform and Analytics Approach
Preliminary results for the year ended 31 December 2024
17 April 2025
Leerink Partners Global Healthcare Conference Transcript
11 March 2025
Preliminary Results for the year ended 31 December 2024
9th April 2025
Improving Manufacturing Conditions: Use of DOEs for Optimal LV Production
